Department of Dermatology, Clinical Research Program, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
PLoS One. 2011;6(7):e22760. doi: 10.1371/journal.pone.0022760. Epub 2011 Jul 28.
Recently, a pathway-based approach has been developed to evaluate the cumulative contribution of the functionally related genes for genome-wide association studies (GWASs), which may help utilize GWAS data to a greater extent.
In this study, we applied this approach for the GWAS of basal cell carcinoma (BCC) of the skin. We first conducted the BCC GWAS among 1,797 BCC cases and 5,197 controls in Caucasians with 740,760 genotyped SNPs. 115,688 SNPs were grouped into gene transcripts within 20 kb in distance and then into 174 Kyoto Encyclopedia of Genes and Genomes pathways, 205 BioCarta pathways, as well as two positive control gene sets (pigmentation gene set and BCC risk gene set). The association of each pathway with BCC risk was evaluated using the weighted Kolmogorov-Smirnov test. One thousand permutations were conducted to assess the significance.
Both of the positive control gene sets reached pathway p-values<0.05. Four other pathways were also significantly associated with BCC risk: the heparan sulfate biosynthesis pathway (p = 0.007, false discovery rate, FDR = 0.35), the mCalpain pathway (p = 0.002, FDR = 0.12), the Rho cell motility signaling pathway (p = 0.011, FDR = 0.30), and the nitric oxide pathway (p = 0.022, FDR = 0.42).
We identified four pathways associated with BCC risk, which may offer new insights into the etiology of BCC upon further validation, and this approach may help identify potential biological pathways that might be missed by the standard GWAS approach.
最近,人们开发出了一种基于通路的方法,用于评估与全基因组关联研究(GWAS)中功能相关基因的累积贡献,这可能有助于更大程度地利用 GWAS 数据。
本研究应用该方法对皮肤基底细胞癌(BCC)的 GWAS 进行了研究。我们首先在高加索人群中进行了 BCC GWAS,该人群包括 1797 例 BCC 病例和 5197 例对照,共 740760 个 SNP 进行了基因分型。将 115688 个 SNP 分为距离 20kb 以内的基因转录本,然后分为 174 个京都基因与基因组百科全书通路、205 个 BioCarta 通路以及两个阳性对照基因集(色素生成基因集和 BCC 风险基因集)。使用加权 Kolmogorov-Smirnov 检验评估每个通路与 BCC 风险的关联。进行了 1000 次置换检验以评估显著性。
两个阳性对照基因集的通路 p 值均<0.05。另外四个通路也与 BCC 风险显著相关:硫酸乙酰肝素生物合成通路(p=0.007,错误发现率 FDR=0.35)、mCalpain 通路(p=0.002,FDR=0.12)、Rho 细胞运动信号通路(p=0.011,FDR=0.30)和一氧化氮通路(p=0.022,FDR=0.42)。
我们确定了四个与 BCC 风险相关的通路,这可能为进一步验证 BCC 的病因学提供新的见解,并且这种方法可能有助于识别标准 GWAS 方法可能遗漏的潜在生物学通路。